Results of the review
Four studies were included for the review of amantadine (one parallel RCT and three crossover RCTs) with 236 participants. Two studies were included for the review of pemoline (one parallel RCT and one crossover RCT) with 126 participants.
In the review of amantadine all studies were open to bias. All studies showed a pattern in favour of amantadine compared with placebo, but there was considerable uncertainty about the validity and clinical significance of the findings. The pattern of benefit was considerably undermined when different assumptions were used in the sensitivity analysis. The effect on patient preference favoured amantadine using optimistic assumptions (RR 1.9, 95% CI: 1.4, 2.7) but favoured placebo using pessimistic, but realistic, assumptions (RR 0.80, 95% CI: 0.62, 1.01). The number of patients reporting side effects ranged from 20 to 60%, with no great difference between treatment and placebo.
In the review of pemoline, both studies were open to bias. There was no overall tendency in favour of pemoline over placebo and an excess of reports of adverse effects with pemoline.
Cost information
The drug costs of amantadine and pemoline are modest (£200 and £80 per annum). No economic evaluations were identified in the systematic review and available data were insufficient to allow modelling of cost-effectiveness in this review.
